EACS 2023 Symposium - The Devil Wears GP120
Related Enduring Materials
What's New
We are pleased to look back on the very successful symposium "The Devil Wears GP120".
The Program Chair and organizers would like to thank the chair, the speakers, and all participants for their contribution and attendance in this symposium!
About this Symposim
Insight into HIV pathogenesis have been key to developing antiretroviral drugs and improving management of people living with HIV. GP120 plays a major role in HIV binding to target cells, but recent studies suggest GP120 may play a much greater role in HIV interactions with the immune system and the appearance of comorbidities. An improved understanding of these interactions may help overcome some of the remaining unmet needs of people living with HIV.
A deeper understanding of GP120 and its relevance as a therapeutic target might be improving the immune reconstitution of patients with poor or partial CD4 responses to suppressive therapy. Although CD4 cells and CD4/CD8 ratios improve in most individuals living with HIV after HIV RNA suppression is maintained, these responses can be blunted in some people living with HIV, such as heavily treatment-experienced individuals and of those starting therapy with very low CD4 counts. Inhibition of GP120 might provide clinical benefit in this population. Additional negative GP120 effects on immune and inflammatory responses might be favourably manipulated with drugs targeting this molecule. This program aims to educate clinicians on recent advances in the study of GP120, and review both basic science as well as clinical data relevant to the topic.
General Information
- Pharmacists, nurses, and other healthcare professionals involved in HIV care.
- Have an improved understanding of the role of GP120 in HIV pathogenesis;
- Be knowledgeable of recent advances in the study of GP120 in HIV pathogenesis;
- Understand the potential for clinical benefits from inhibition of GP120 regarding immune reconstitution and anti-inflammation;
- Be knowledgeable of the current laboratory and clinical data supporting these concepts; and
- Have an improved ability to interpret future GP120 research.
Practical Information
The Symposium took place in Session Room 1 - Polonez
Translation will not be provided.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Program Director
The EACS 2023 Symposium - The Devil Wears GP120 is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Accreditation Statement
The The Devil Wears GP120, Warsaw, Poland 18/10/2023 - 18/10/2023, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Claim CME Credits
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applictations .
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Please note that CME accreditation is only provided for delegates that attend the event.
